[{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Parecoxib Sodium","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Parecoxib (Sodium)

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Parecoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Parecoxib Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          First Affiliated Hospital, Sun Yat-Sen University

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          First Affiliated Hospital, Sun Yat-Sen University

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Parecoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Emergence Delirium.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 14, 2010

                          Lead Product(s) : Parecoxib Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Xianwei Zhang

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Xianwei Zhang

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Parecoxib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 23, 2010

                          Lead Product(s) : Parecoxib Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank